已入深夜,您辛苦了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!祝你早点完成任务,早点休息,好梦!

Lenvatinib and everolimus synergistically inhibit neuroendocrine neoplasms by upregulating ITGB4 expression

依维莫司 伦瓦提尼 癌症研究 体内 医学 下调和上调 细胞凋亡 神经内分泌肿瘤 药理学 体外 免疫印迹 细胞生长 抑制性突触后电位 细胞 化学 细胞培养 靶向治疗 流式细胞术 PD-L1
作者
Liping Xie,Yaning Bo,Mei Yang,Qi Gui,Min Tao
出处
期刊:Endocrine-related Cancer [Bioscientifica]
卷期号:33 (1): e250233-
标识
DOI:10.1530/erc-25-0233
摘要

There are currently few treatment options available for advanced neuroendocrine neoplasms (NENs). When treating metastatic renal cancer, the combination of lenvatinib with everolimus has shown noticeably greater success than monotherapy. Clarifying the synergistic effects of lenvatinib and everolimus on NENs and investigating the underlying processes were the goals of this study. Lenvatinib and everolimus were tested for their synergistic inhibitory effects on NEN cells in vitro using CCK-8, colony formation, wound healing, flow cytometry, and tube formation. In vivo evaluation of the combined inhibitory effects was conducted using a xenograft mouse model. Western blot analysis was used to look into the main regulatory molecules implicated in this synergy, and clinical case studies were used to quantify the clinical benefits. The combination of lenvatinib and everolimus showed a synergistic anti-tumor impact in vivo and suppressed cell proliferation, colony formation, cell migration, angiogenesis, and promoted apoptosis in vitro. Notably, in patients with advanced NENs who developed resistance after many lines of therapy (>2nd line), this combination successfully postponed the advancement of their disease. Mechanistically, both medications increased the expression of ITGB4 and inhibited 4EBP1 phosphorylation; their combined inhibitory effects on NENs were lessened when ITGB4 was knocked down. These findings indicate that lenvatinib and everolimus act synergistically to inhibit NEN proliferation and migration and to induce apoptosis in vitro, with robust synergistic activity also evident in vivo. This synergy appears to be mediated, at least in part, through the upregulation of ITGB4.

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
pppyc完成签到 ,获得积分10
刚刚
3秒前
余香的应助被第四周期采纳,获得10
3秒前
老实惜海完成签到,获得积分10
3秒前
情怀的应助被tejing1158采纳,获得10
3秒前
小蘑菇的应助被richardhipower采纳,获得10
5秒前
kelaibing发布了新的文献求助10
5秒前
所所的应助被歪歪采纳,获得10
5秒前
mofudyc发布了新的文献求助10
6秒前
qingqingdandan完成签到 ,获得积分10
7秒前
7秒前
8秒前
sln完成签到,获得积分20
10秒前
阿南发布了新的文献求助10
11秒前
科目三的应助被tejing1158采纳,获得10
12秒前
巴斯光年发布了新的文献求助10
12秒前
12秒前
慕青的应助被xc采纳,获得10
12秒前
14秒前
东东完成签到 ,获得积分10
17秒前
xiaoyu完成签到,获得积分10
17秒前
18秒前
草根努力记完成签到 ,获得积分10
19秒前
Aspire完成签到 ,获得积分10
19秒前
xx发布了新的文献求助10
20秒前
21秒前
kelaibing完成签到,获得积分10
21秒前
Yao完成签到,获得积分10
21秒前
烟花的应助被tejing1158采纳,获得10
22秒前
wzx发布了新的文献求助10
22秒前
魏子合完成签到 ,获得积分10
23秒前
巴斯光年完成签到,获得积分20
24秒前
阿南发布了新的文献求助10
24秒前
gghjgjkgui完成签到,获得积分10
25秒前
田様的应助被Postgraduate-Z采纳,获得10
25秒前
ifast完成签到 ,获得积分10
27秒前
上官若男的应助被xc采纳,获得10
27秒前
天天快乐的应助被mofudyc采纳,获得10
28秒前
28秒前
29秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 2000
Sex, Aging, and Death in a Medieval Medical Compendium: Trinity College Cambridge MS R.14.52, Its Texts, Language, and Scribe 500
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
基于结构调控的功能化水诱导发电材料与器件研究 500
基于界面调控的高效湿气发电材料与器件研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8189722
求助须知:如何正确求助?哪些是违规求助? 9576968
关于积分的说明 21850614
捐赠科研通 7787686
什么是DOI,文献DOI怎么找? 3435771
关于科研通互助平台的介绍 2559813
邀请新用户注册赠送积分活动 2482639